Search

Search bills, members, committees and pages...

S. 3014

U.S. SenateIn Senate Committee

Summary

S. 3014, the Ensuring Timely Access to Generics Act of 2025, was introduced in the Senate on Oct 16, 2025 by Sen. Jeanne Shaheen (D) with 2 co-sponsors. It was referred to Health, Education, Labor, And Pensions, and last saw action on Oct 16, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.


Record

Text

S. 3014 has 2 co-sponsors.

sb3014/introduced-in-senate.txt
119 S3014 IS: Ensuring Timely Access to Generics Act of 2025
U.S. Senate
2025-10-16
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
II
119th CONGRESS
1st Session
S. 3014
IN THE SENATE OF THE UNITED STATES
October 16, 2025
Mrs. Shaheen (for herself and Ms. Collins ) introduced the following bill; which was
read twice and referred to the Committee on
Health, Education, Labor, and Pensions
A BILL
To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen
petitions.
1.
Short title
This Act may be cited as the Ensuring Timely Access to Generics Act of 2025 .
2.
Ensuring timely access to generics
Section 505(q) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(q) ) is amended—
(1)
in paragraph (1)—
(A)
in subparagraph (A)(i), by inserting , 10.31, after 10.30 ;
(B)
in subparagraph (E)—
(i)
by striking application and and inserting application or ;
(ii)
by striking If the Secretary and inserting the following:
(i)
In general
If the Secretary
; and
(iii)
by striking the second sentence and inserting the following:
(ii)
Primary purpose of delaying
(I)
In general
In determining whether a petition was submitted with the primary purpose of delaying an application, the Secretary may consider the following factors:
(aa)
Whether the petition was submitted in accordance with paragraph (2)(B), based on when the petitioner knew the relevant information relied upon to form the basis of such petition.
(bb)
When the petition was submitted in relation to when the petitioner reasonably should have known the relevant information relied upon to form the basis of such petition.
(cc)
Whether the petitioner has submitted multiple or serial petitions or supplements to petitions raising issues that reasonably could have been known to the petitioner at the time of submission of the earlier petition or petitions.
(dd)
Whether the petition was submitted close in time to a known, first date upon which an application under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act could be approved.
(ee)
Whether the petition was submitted without relevant data or information in support of the scientific positions forming the basis of such petition.
(ff)
Whether the petition raises the same or substantially similar issues as a prior petition to which the Secretary has responded substantively already, including if the subsequent submission follows such response from the Secretary closely in time.
(gg)
Whether the petition requests changing the applicable standards that other applicants are required to meet, including requesting testing, data, or labeling standards that are more onerous or rigorous than the standards the Secretary has determined to be applicable to the listed drug, reference product, or petitioner’s version of the same drug.
(hh)
The petitioner's record of submitting petitions to the Food and Drug Administration that have been determined by the Secretary to have been submitted with the primary purpose of delay.
(ii)
Other relevant and appropriate factors, which the Secretary shall describe in guidance.
(II)
Guidance
The Secretary may issue or update guidance, as appropriate, to describe factors the Secretary considers in accordance with subclause (I).
;
(C)
by striking subparagraph (F);
(D)
by redesignating subparagraphs (G) through (I) as subparagraphs (F) through (H), respectively; and
(E)
in subparagraph (H), as so redesignated, by striking submission of this petition and inserting submission of this document ;
(2)
in paragraph (2)—
(A)
by redesignating subparagraphs (A) through (C) as subparagraphs (C) through (E), respectively;
(B)
by inserting before subparagraph (C), as so redesignated, the following:
(A)
In general
A person shall submit a petition to the Secretary under paragraph (1) before filing a civil action in which the person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act. Such petition and any supplement to such a petition shall describe all information and arguments that form the basis of the relief requested in any civil action described in the previous sentence.
(B)
Timely submission of citizen petition
A petition and any supplement to a petition shall be submitted within 180 days after the person knew the information that forms the basis of the request made in the petition or supplement.
;
(C)
in subparagraph (C), as so redesignated—
(i)
in the heading, by striking
within 150 days ;
(ii)
in clause (i), by striking during the 150-day period referred to in paragraph (1)(F), ; and
(iii)
by amending clause (ii) to read as follows:
(ii)
on or after the date that is 151 days after the date of submission of the petition, the Secretary approves or has approved the application that is the subject of the petition without having made such a final decision.
;
(D)
by amending subparagraph (D), as so redesignated, to read as follows:
(D)
Dismissal of certain civil actions
(i)
Petition
If a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (A), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.
(ii)
Timeliness
If a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (B), the court shall dismiss with prejudice the action for failure to timely file a petition.
(iii)
Final response
If a civil action is filed against the Secretary with respect to any issue raised in a petition timely filed under paragraph (1) in which the petitioner requests that the Secretary take any form of action that could, if taken, set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act before the Secretary has taken final agency action on the petition within the meaning of subparagraph (C), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.
; and
(E)
in clause (iii) of subparagraph (E), as so redesignated, by striking as defined under subparagraph (2)(A) and inserting within the meaning of subparagraph (C) ; and
(3)
in paragraph (4)—
(A)
by striking
Exceptions in the paragraph heading and all that follows through This subsection does and inserting
Exceptions.— This subsection does ;
(B)
by striking subparagraph (B); and
(C)
by redesignating clauses (i) and (ii) as subparagraphs (A) and (B), respectively, and adjusting the margins accordingly.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-10-16
  2. Passed Senate
  3. Passed House
  4. Conference
  5. To President
  6. Became Law

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.

Sponsors

Sen. Jeanne Shaheen (D) sponsors S. 3014, and 2 members have co-sponsored it, 1 of them from the day it was introduced.

Committees

S. 3014 went before 1 committee: Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions
Health, Education, Labor, and Pensions
Referred To · Oct 16, 2025 · 747 Bills

Actions

S. 3014 has taken 2 actions since Oct 16, 2025.

ChamberAction
Oct 16, 2025
Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Health, Education, Labor, and Pensions Committee
Oct 16, 2025
Introduced in Senate

Votes

S. 3014 has not gone to a roll call.

1 bill is related to S. 3014.

Titles

S. 3014 goes by 3 titles, 1 of them short titles.

  • Ensuring Timely Access to Generics Act of 2025 — Display Title
  • Ensuring Timely Access to Generics Act of 2025 — Short Title(s) as Introduced
  • A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. — Official Title as Introduced

Lobbying

20 clients hired 21 firms and 134 registered lobbyists who named S. 3014 in 30 quarterly filings, 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Medicare/Medicaid, Pharmacy, Health Issues, Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Budget/Appropriations, Trade (domestic/foreign), Small Business.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGA coalition of organizations working on market-based solutions to drug pricing.District of Columbia12$180K
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)Coalition to promote lowering prescription drug prices.District of Columbia12$100K
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICArepresents biopharmaceutical research companiesDistrict of Columbia22$50K
BCBSM INCMinnesota12
BLUE CROSS AND BLUE SHIELD ASSOCIATIONDistrict of Columbia12
BLUE CROSS AND BLUE SHIELD OF FLORIDA INCFlorida12
BLUE CROSS AND BLUE SHIELD OF KANSAS INCKansas12
BLUE CROSS BLUE SHIELD OF MICHIGANDistrict of Columbia12
BLUECROSS BLUESHIELD OF TENNESSEETennessee12
GUIDEWELL MUTUAL HOLDING CORPORATIONFlorida12
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCDistrict of Columbia11$220K
AMGENBiotechnology.California11$60K
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)Trade Organization for Generic Drug Manufacturers and DistributersDistrict of Columbia11$60K
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONPharmaceutical Industry Labor Management Association.Virginia11$30K
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTSMaryland11
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)District of Columbia11
BIOTECHNOLOGY INNOVATION ORGANIZATIONDistrict of Columbia11
GSK (FKA GLAXOSMITHKLINE INC.)District of Columbia11
KAISER FOUNDATION HEALTH PLAN INCCalifornia11
SMALL BUSINESS & ENTREPRENEURSHIP COUNCIL (SBE COUNCIL)Virginia11

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 134.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 second_quarter$7.4M2nd Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2026 second_quarter$3M2nd Quarter - Report
BIOTECHNOLOGY INNOVATION ORGANIZATIONBIOTECHNOLOGY INNOVATION ORGANIZATION2026 second_quarter$2.4M2nd Quarter - Report
BLUE CROSS AND BLUE SHIELD ASSOCIATIONBLUE CROSS AND BLUE SHIELD ASSOCIATION2026 first_quarter$1.5M1st Quarter - Report
BLUE CROSS AND BLUE SHIELD ASSOCIATIONBLUE CROSS AND BLUE SHIELD ASSOCIATION2026 second_quarter$990K2nd Quarter - Report
GSK (FKA GLAXOSMITHKLINE INC.)GSK (FKA GLAXOSMITHKLINE INC.)2026 second_quarter$890K2nd Quarter - Report
KAISER FOUNDATION HEALTH PLAN INCKAISER FOUNDATION HEALTH PLAN INC.2026 second_quarter$530K2nd Quarter - Report
BLUE CROSS BLUE SHIELD OF MICHIGANBLUE CROSS BLUE SHIELD OF MICHIGAN2026 second_quarter$276.3K2nd Quarter - Report
BLUE CROSS BLUE SHIELD OF MICHIGANBLUE CROSS BLUE SHIELD OF MICHIGAN2026 first_quarter$276.3K1st Quarter - Report
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTSAMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS2026 second_quarter$260K2nd Quarter - Report
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP2026 second_quarter$220K2nd Quarter - Report
BLUECROSS BLUESHIELD OF TENNESSEEBLUECROSS BLUESHIELD OF TENNESSEE2026 first_quarter$220K1st Quarter - Report
BLUECROSS BLUESHIELD OF TENNESSEEBLUECROSS BLUESHIELD OF TENNESSEE2026 second_quarter$140K2nd Quarter - Report
BLUE CROSS AND BLUE SHIELD OF FLORIDA INCBLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.2026 first_quarter$130K1st Quarter - Report
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.2026 second_quarter$90K2nd Quarter - Report
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.2026 first_quarter$90K1st Quarter - Report
BLUE CROSS AND BLUE SHIELD OF FLORIDA INCBLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.2026 second_quarter$80K2nd Quarter - Report
AMGENTHE NICKLES GROUP, LLC2026 second_quarter$60K2nd Quarter - Report
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)FIERCE GOVERNMENT RELATIONS2026 second_quarter$60K2nd Quarter - Report
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC2026 second_quarter$50K2nd Quarter - Termina…

Classification

The Congressional Research Service files S. 3014 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 3014’s is Health.

s3014/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com